MAPT and Alzheimer disease: Second, cortical measurements of amyloid-beta and tau depositions via magnetic resonance imaging (MRI) and positron emission tomography (PET) [9] are expensive and thus not accessible on the scale needed for a public health challenge such as AD [8,11].